FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307021407> ?p ?o ?g. }

• W4307021407 endingPage "198" @default.
• W4307021407 startingPage "191" @default.
• W4307021407 abstract "DESTINY-Breast03 (NCT03529110) was the first global phase III study to assess the antitumor activity of trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine (T-DM1) in 2022. However, the balance between efficacy and cost of T-DXd remains unclear. As a result, the present study's goal is to investigate the cost-effectiveness of T-DXd vs T-DM1 as a second-line treatment for patients with HER2-positive MBC from the US and Chinese payer's perspectives.A Markov model with a 20-year time horizon was developed to evaluate the overall cost of patient treatment, incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and life-years (LYs) in the US and China at WTP levels of 150,000/QALY and 37,653/QALY, respectively (3 times GDP per capita in 2021). Key data were gathered from the US government's official website, the Xiangya Hospital of Central South University, and published literature. To determine the model's stability, a sensitivity analysis was performed. A subgroup analysis was also implemented.Compared with T-DM1, treatment with T-DXd generated an additional 1.672 QALYs (2.796 LYs), resulting in an ICER of $13,342/QALY (US) and $186,017/QALY (China). The cost of drugs is the most influential factor in the American and Chinese models. Subgroup analysis revealed that the T-DXd and T-DM1 regimens were more cost-effective at reducing the risk of death in the US and Chinese HER2-positive MBC patients.T-DXd as second-line treatment could gain more health benefits for HER2-positive MBC patients in comparison with T-DM1, which is considered to be cost-effective in the US but not in China." @default.
• W4307021407 created "2022-10-22" @default.
• W4307021407 creator A5015102287 @default.
• W4307021407 creator A5019483797 @default.
• W4307021407 creator A5050501022 @default.
• W4307021407 creator A5085248434 @default.
• W4307021407 creator A5089868907 @default.
• W4307021407 date "2022-12-01" @default.
• W4307021407 modified "2023-10-18" @default.
• W4307021407 title "Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis" @default.
• W4307021407 cites W2020677481 @default.
• W4307021407 cites W2050056063 @default.
• W4307021407 cites W2078892025 @default.
• W4307021407 cites W2159967578 @default.
• W4307021407 cites W2281842333 @default.
• W4307021407 cites W2343295136 @default.
• W4307021407 cites W2512440162 @default.
• W4307021407 cites W2547768673 @default.
• W4307021407 cites W2597334931 @default.
• W4307021407 cites W2600333833 @default.
• W4307021407 cites W2914603195 @default.
• W4307021407 cites W2915456024 @default.
• W4307021407 cites W2944954139 @default.
• W4307021407 cites W2977067943 @default.
• W4307021407 cites W2989987240 @default.
• W4307021407 cites W2991564522 @default.
• W4307021407 cites W2996630100 @default.
• W4307021407 cites W3010615593 @default.
• W4307021407 cites W3025967965 @default.
• W4307021407 cites W3029013041 @default.
• W4307021407 cites W3044336467 @default.
• W4307021407 cites W3047417707 @default.
• W4307021407 cites W3207557929 @default.
• W4307021407 cites W4200232423 @default.
• W4307021407 cites W4211005384 @default.
• W4307021407 cites W4225845169 @default.
• W4307021407 cites W4226051140 @default.
• W4307021407 cites W4281640394 @default.
• W4307021407 doi "https://doi.org/10.1016/j.breast.2022.10.010" @default.
• W4307021407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36327624" @default.
• W4307021407 hasPublicationYear "2022" @default.
• W4307021407 type Work @default.
• W4307021407 citedByCount "5" @default.
• W4307021407 countsByYear W43070214072023 @default.
• W4307021407 crossrefType "journal-article" @default.
• W4307021407 hasAuthorship W4307021407A5015102287 @default.
• W4307021407 hasAuthorship W4307021407A5019483797 @default.
• W4307021407 hasAuthorship W4307021407A5050501022 @default.
• W4307021407 hasAuthorship W4307021407A5085248434 @default.
• W4307021407 hasAuthorship W4307021407A5089868907 @default.
• W4307021407 hasBestOaLocation W43070214071 @default.
• W4307021407 hasConcept C112930515 @default.
• W4307021407 hasConcept C121608353 @default.
• W4307021407 hasConcept C126322002 @default.
• W4307021407 hasConcept C143998085 @default.
• W4307021407 hasConcept C2775930923 @default.
• W4307021407 hasConcept C2778087150 @default.
• W4307021407 hasConcept C2779786085 @default.
• W4307021407 hasConcept C3019080777 @default.
• W4307021407 hasConcept C515549039 @default.
• W4307021407 hasConcept C530470458 @default.
• W4307021407 hasConcept C71924100 @default.
• W4307021407 hasConceptScore W4307021407C112930515 @default.
• W4307021407 hasConceptScore W4307021407C121608353 @default.
• W4307021407 hasConceptScore W4307021407C126322002 @default.
• W4307021407 hasConceptScore W4307021407C143998085 @default.
• W4307021407 hasConceptScore W4307021407C2775930923 @default.
• W4307021407 hasConceptScore W4307021407C2778087150 @default.
• W4307021407 hasConceptScore W4307021407C2779786085 @default.
• W4307021407 hasConceptScore W4307021407C3019080777 @default.
• W4307021407 hasConceptScore W4307021407C515549039 @default.
• W4307021407 hasConceptScore W4307021407C530470458 @default.
• W4307021407 hasConceptScore W4307021407C71924100 @default.
• W4307021407 hasFunder F4320335740 @default.
• W4307021407 hasLocation W43070214071 @default.
• W4307021407 hasLocation W43070214072 @default.
• W4307021407 hasLocation W43070214073 @default.
• W4307021407 hasLocation W43070214074 @default.
• W4307021407 hasOpenAccess W4307021407 @default.
• W4307021407 hasPrimaryLocation W43070214071 @default.
• W4307021407 hasRelatedWork W2481553405 @default.
• W4307021407 hasRelatedWork W2905960639 @default.
• W4307021407 hasRelatedWork W2939485277 @default.
• W4307021407 hasRelatedWork W3013160810 @default.
• W4307021407 hasRelatedWork W3088751691 @default.
• W4307021407 hasRelatedWork W3092625235 @default.
• W4307021407 hasRelatedWork W3123611170 @default.
• W4307021407 hasRelatedWork W3174405896 @default.
• W4307021407 hasRelatedWork W4210581512 @default.
• W4307021407 hasRelatedWork W4376320886 @default.
• W4307021407 hasVolume "66" @default.
• W4307021407 isParatext "false" @default.
• W4307021407 isRetracted "false" @default.
• W4307021407 workType "article" @default.